IDEAYA Biosciences is a clinical-stage precision oncology company with no approved products yet, focused on developing targeted cancer therapies that exploit genetic vulnerabilities in tumor cells — a concept it calls "synthetic lethality." IDEAYA's lead program is darovasertib, an oral PKC inhibitor for uveal melanoma (UM), a rare eye cancer with no currently approved systemic therapies for most patients. Darovasertib is being developed in combination with Pfizer's crizotinib across metastatic, neoadjuvant, and adjuvant UM settings, with a Phase 2/3 registrational trial expected to report topline data in Q1 2026, potentially supporting an accelerated U.S. approval filing. IDEAYA plans to commercialize darovasertib directly in the U.S. using a specialty sales force, given the small and concentrated UM patient population. Servier holds ex-U.S. rights to darovasertib for $210M upfront plus up to $320M in milestones and royalties. Beyond darovasertib, IDEAYA's pipeline includes IDE849, a DLL3-targeting antibody-drug conjugate (ADC) in-licensed from Hengrui for development in small-cell lung cancer; IDE397, an oral MAT2A inhibitor targeting MTAP-deleted solid tumors; and several earlier-stage programs pairing DDR inhibitors with ADCs. IDEAYA funds operations through equity and partnership deals, combining internal drug discovery — using its own compound libraries and CRISPR-based synthetic lethality tools — with selective in-licensing of ADCs that complement its DDR inhibitor portfolio, and out-licensing geographic rights to partners.